{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Lupus nephritis", "azathioprine", "belimumab", "cyclophosphamide", "cyclosporine A", "leflunomide", "mycophenolate mofetil", "tacrolimus", "voclosporin"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38087473", "DateCompleted": {"Year": "2023", "Month": "12", "Day": "16"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "12", "Day": "12"}], "Language": ["eng"], "ELocationID": ["2290365", "10.1080/0886022X.2023.2290365"], "Journal": {"ISSN": "1525-6049", "JournalIssue": {"Volume": "45", "Issue": "2", "PubDate": {"Year": "2023"}}, "Title": "Renal failure", "ISOAbbreviation": "Ren Fail"}, "ArticleTitle": "The efficacy of immunosuppressive drugs induction therapy for lupus nephritis: a systematic review and network meta-analysis.", "Pagination": {"StartPage": "2290365", "MedlinePgn": "2290365"}, "Abstract": {"AbstractText": ["This study was to assess the safety and effectiveness of immunosuppressive agents, specifically Voclosporin, when used in conjunction with mycophenolate mofetil (MMF) induction therapy for the management of lupus nephritis (LN).", "A systematic review and network meta-analysis (NMA) was conducted on randomized controlled trials investigating the efficacy of immunosuppressant-induced therapy for LN. The random effects model was used in the analysis. I<sup>2</sup> was used to evaluate the heterogeneity of the model. Odds ratios (OR) and 95% credible intervals (CrI) were computed to assess and compare the relative effectiveness and safety of various treatment protocols.", "The study included a total of 16 randomized controlled trials (RCTs) involving 2444 patients with LN. The analysis results indicated that there was no significant difference in terms of partial remission (PR) between the drugs. However, when considering complete remission (CR), the combination of Voclosporin with MMF showed the highest remission rate, followed by Tacrolimus (TAC). Unfortunately, Voclosporin in combination with MMF had the highest risk of infection and serious infection, indicating a lower safety profile.", "Voclosporin in combination with MMF demonstrated the highest efficacy as an induction therapy for LN. However, it should be noted that the risk of infection and serious infection was found to be high with this regimen. On the other hand, TAC not only showed efficacy but also had a lower risk of infection and serious infection, making it a favorable option in terms of safety. This study did' not include results on other adverse events."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy; Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China."}], "LastName": "Dong", "ForeName": "Yongqiang", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy; Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "College of Plant Science and Technology, Innovation Academy of International Traditional Chinese Medicinal Materials, National-Regional Joint Engineering Research Center in Hubei for Medici Hubei University of Medicinal Plant Breeding and Cultivation, Huazhong Agricultural University, Wuhan, China."}, {"Identifier": [], "Affiliation": "Medicinal Plant Engineering Research Center of Hubei Province, Institute for Medicinal Plants, Huazhong Agricultural University, Wuhan, China."}], "LastName": "Shi", "ForeName": "Jinmin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy; Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China."}], "LastName": "Wang", "ForeName": "Shanshan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy; Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China."}], "LastName": "Liu", "ForeName": "Yanhong", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy; Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China."}], "LastName": "Yu", "ForeName": "Shirong", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy; Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "Laboratory of Chinese Herbal Pharmacology, Department of Pharmacy, Renmin Hospital; Biomedical Research Institute; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, China."}, {"Identifier": [], "Affiliation": "College of Plant Science and Technology, Innovation Academy of International Traditional Chinese Medicinal Materials, National-Regional Joint Engineering Research Center in Hubei for Medici Hubei University of Medicinal Plant Breeding and Cultivation, Huazhong Agricultural University, Wuhan, China."}, {"Identifier": [], "Affiliation": "Medicinal Plant Engineering Research Center of Hubei Province, Institute for Medicinal Plants, Huazhong Agricultural University, Wuhan, China."}], "LastName": "Zhao", "ForeName": "Lijun", "Initials": "L"}], "PublicationTypeList": ["Meta-Analysis", "Systematic Review", "Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Ren Fail", "NlmUniqueID": "8701128", "ISSNLinking": "0886-022X"}, "ChemicalList": [{"RegistryNumber": "8N3DW7272P", "NameOfSubstance": "Cyclophosphamide"}, {"RegistryNumber": "0", "NameOfSubstance": "Immunosuppressive Agents"}, {"RegistryNumber": "WM0HAQ4WNM", "NameOfSubstance": "Tacrolimus"}, {"RegistryNumber": "HU9DX48N0T", "NameOfSubstance": "Mycophenolic Acid"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Lupus Nephritis"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Cyclophosphamide"}, {"QualifierName": [], "DescriptorName": "Induction Chemotherapy"}, {"QualifierName": [], "DescriptorName": "Network Meta-Analysis"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Immunosuppressive Agents"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Tacrolimus"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Mycophenolic Acid"}, {"QualifierName": [], "DescriptorName": "Remission Induction"}, {"QualifierName": [], "DescriptorName": "Randomized Controlled Trials as Topic"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Jaryal A, Vikrant S.. Current status of lupus nephritis. Indian J Med Res. 2017;145(2):1\u20139. doi: 10.4103/ijmr.IJMR_163_16.", "ArticleIdList": ["10.4103/ijmr.IJMR_163_16", "PMC5501048", "28639592"]}, {"Citation": "Houssiau FA, Lauwerys BR.. Current management of lupus nephritis. Best practice & research. Clin Rheumatol. 2013;27(3):319\u2013328.", "ArticleIdList": ["24238689"]}, {"Citation": "Hogan J, Appel GB.. Update on the treatment of lupus nephritis. Curr Opin Nephrol Hypertens. 2013;22(2):224\u2013230. doi: 10.1097/MNH.0b013e32835d921c.", "ArticleIdList": ["10.1097/MNH.0b013e32835d921c", "23328501"]}, {"Citation": "Blanco FJ, G\u00f3mez-Reino JJ, de la Mata J, et al. . Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus. 1998;7(3):159\u2013163. doi: 10.1191/096120398678919930.", "ArticleIdList": ["10.1191/096120398678919930", "9607639"]}, {"Citation": "Bomback AS, Appel GB.. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028\u20132035. doi: 10.1681/ASN.2010050472.", "ArticleIdList": ["10.1681/ASN.2010050472", "21051743"]}, {"Citation": "Schwartz N, Goilav B, Putterman C.. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26(5):502\u2013509. doi: 10.1097/BOR.0000000000000089.", "ArticleIdList": ["10.1097/BOR.0000000000000089", "PMC4221732", "25014039"]}, {"Citation": "Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. . Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. The J Rheumatol. 2005;32(5):913\u2013919.", "ArticleIdList": ["15868630"]}, {"Citation": "Chambers SA, Raine R, Rahman A, et al. . Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology. 2009;48(3):266\u2013271. doi: 10.1093/rheumatology/ken479.", "ArticleIdList": ["10.1093/rheumatology/ken479", "19151034"]}, {"Citation": "Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus. 2004;13(5):366\u2013371. doi: 10.1191/0961203303lu1028oa.", "ArticleIdList": ["10.1191/0961203303lu1028oa", "15230294"]}, {"Citation": "Appel GB, Contreras G, Dooley MA, et al. . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103\u20131112. doi: 10.1681/ASN.2008101028.", "ArticleIdList": ["10.1681/ASN.2008101028", "PMC2678035", "19369404"]}, {"Citation": "Lee YH, Song GG.. Comparative efficacy and safety of tacrolimus, cyclosporin A, mycophenolate mofetil, cyclophosphamide, and corticosteroids as induction therapy for membranous lupus nephritis: a network meta-analysis. Pharmacology. 2022;107(9\u2009\u2212\u200910):439\u2013445. doi: 10.1159/000525066.", "ArticleIdList": ["10.1159/000525066", "35609529"]}, {"Citation": "Rovin BH, Teng YKO, Ginzler EM, et al. . Efficacy and safety of voclosporin versus placebo for lupus nephritis (Aurora 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070\u20132080. doi: 10.1016/S0140-6736(21)00578-X.", "ArticleIdList": ["10.1016/S0140-6736(21)00578-X", "33971155"]}, {"Citation": "Rovin BH, Solomons N, Pendergraft WF, et al. . A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2018;95(1):219\u2013231. doi: 10.1016/j.kint.2018.08.025.", "ArticleIdList": ["10.1016/j.kint.2018.08.025", "30420324"]}, {"Citation": "Bitencourt Dias C, Pinheiro CC, Malafronte P, et al. . Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. Clin Nephrol. 2011;76(1):57\u201363. doi: 10.5414/cn106689.", "ArticleIdList": ["10.5414/cn106689", "21722606"]}, {"Citation": "Stewart LA, Clarke M, Rovers M, et al. . Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657\u20131665. doi: 10.1001/jama.2015.3656.", "ArticleIdList": ["10.1001/jama.2015.3656", "25919529"]}, {"Citation": "Higgins JP, Green S.. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. The cochrane collaboration. 2011; Available from: www.handbook.cochrane.org."}, {"Citation": "Lin C, Xin S, Qin X, et al. . Zoledronic acid suppresses metastasis of esophageal squamous cell carcinoma cells through upregulating the tight junction protein occludin. Cytotechnology. 2016;68(4):1233\u20131241. doi: 10.1007/s10616-015-9884-7.", "ArticleIdList": ["10.1007/s10616-015-9884-7", "PMC4960172", "26204820"]}, {"Citation": "Kiper HD, Tezcanli Kaymaz B, Gokbulut AA, et al. . STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomed Pharmacother. 2013;67(6):527\u2013532. doi: 10.1016/j.biopha.2013.04.006.", "ArticleIdList": ["10.1016/j.biopha.2013.04.006", "23725755"]}, {"Citation": "Zheng Z, Zhang H, Peng X, et al. . Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis a randomized clinical trial. JAMA Netw Open. 2022;5(3):e224492. doi: 10.1001/jamanetworkopen.2022.4492.", "ArticleIdList": ["10.1001/jamanetworkopen.2022.4492", "PMC8969066", "35353167"]}, {"Citation": "Furie R, Rovin BH, Houssiau F, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117\u20131128. doi: 10.1056/NEJMoa2001180.", "ArticleIdList": ["10.1056/NEJMoa2001180", "32937045"]}, {"Citation": "Zhang M, Qi C, Zha Y, et al. . Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin Rheumatol. 2019;38(3):859\u2013867. doi: 10.1007/s10067-018-4348-z.", "ArticleIdList": ["10.1007/s10067-018-4348-z", "30426311"]}, {"Citation": "Sedhain A, Hada R, Agrawal RK, et al. . Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial. BMC Nephrol. 2018;19(1):175. doi: 10.1186/s12882-018-0973-7.", "ArticleIdList": ["10.1186/s12882-018-0973-7", "PMC6042432", "29996800"]}, {"Citation": "Mehra S, Usdadiya JB, Jain VK, et al. . Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int. 2018;38(4):557\u2013568. doi: 10.1007/s00296-018-3995-3.", "ArticleIdList": ["10.1007/s00296-018-3995-3", "29450636"]}, {"Citation": "Liu Z, Zhang H, Liu Z, et al. . Multitarget therapy for induction treatment of lupus nephritis a randomized trial. Ann Intern Med. 2015;162(1):18\u201326. doi: 10.7326/M14-1030.", "ArticleIdList": ["10.7326/M14-1030", "25383558"]}, {"Citation": "Rathi M, Goyal A, Jaryal A, et al. . Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016;89(1):235\u2013242. doi: 10.1038/ki.2015.318.", "ArticleIdList": ["10.1038/ki.2015.318", "26489028"]}, {"Citation": "Mok CC, Ying KY, Yim CW, et al. . Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30\u201336. doi: 10.1136/annrheumdis-2014-206456.", "ArticleIdList": ["10.1136/annrheumdis-2014-206456", "25550339"]}, {"Citation": "Li X, Ren H, Zhang Q, et al. . Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4):1467\u20131472. doi: 10.1093/ndt/gfr484.", "ArticleIdList": ["10.1093/ndt/gfr484", "21917733"]}, {"Citation": "Chen W, Tang X, Liu Q, et al. . Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235\u2013244. doi: 10.1053/j.ajkd.2010.08.036.", "ArticleIdList": ["10.1053/j.ajkd.2010.08.036", "21177013"]}, {"Citation": "Zavada J, Pesickova S, Rysava R, et al. . Cyclosporine a or intravenous cyclophosphamide for lupus nephritis: the cyclofa-lune study. Lupus. 2010;19(11):1281\u20131289. doi: 10.1177/0961203310371155.", "ArticleIdList": ["10.1177/0961203310371155", "20605876"]}, {"Citation": "El-Shafey EM, Abdou SH, Shareef MM.. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol. 2010;14(3):214\u2013221. doi: 10.1007/s10157-010-0270-7.", "ArticleIdList": ["10.1007/s10157-010-0270-7", "20169461"]}, {"Citation": "Ong LM, Hooi LS, Lim TO, et al. . Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology. 2005;10(5):504\u2013510. doi: 10.1111/j.1440-1797.2005.00444.x.", "ArticleIdList": ["10.1111/j.1440-1797.2005.00444.x", "16221103"]}, {"Citation": "Ginzler EM, Dooley MA, Aranow C, et al. . Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219\u20132228. doi: 10.1056/NEJMoa043731.", "ArticleIdList": ["10.1056/NEJMoa043731", "16306519"]}, {"Citation": "Li K, Yu Y, Gao Y, et al. . Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: a systematic review and network meta-analysis. Front Immunol. 2022;13:859380. doi: 10.3389/fimmu.2022.859380.", "ArticleIdList": ["10.3389/fimmu.2022.859380", "PMC9013779", "35444666"]}, {"Citation": "Zandman-Goddard G, Shoenfeld Y, Zandman-Goddard G, et al. . Infections and SLE. Autoimmunity. 2009;38(7):473\u2013485. doi: 10.1080/08916930500285352.", "ArticleIdList": ["10.1080/08916930500285352", "16373252"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "12", "Day": "17", "Hour": "9", "Minute": "44"}, {"Year": "2023", "Month": "12", "Day": "13", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "12", "Day": "13", "Hour": "0", "Minute": "33"}, {"Year": "2023", "Month": "12", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38087473", "PMC11001324", "10.1080/0886022X.2023.2290365"]}}], "PubmedBookArticle": []}